EKF Diagnostics Investor Announcements

EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

Pages:

19

TR-1 notification of major interest in shares

12^th Jul 2016

Director / PDMR Shareholding

12^th Jul 2016

Directorate Change

11^th Jul 2016

EKF Diagnostics announces the appointment of Carl Dominic Contadini, an Operational Adviser to Harwood Capital LLP, as Non-Executive Director with immediate effect.

6^th Jul 2016

EKF Diagnostics Holdings plc provides the following update on trading for the six months ended 30 June 2016.

Director / PDMR Shareholding

27^th Jun 2016

Director / PDMR Shareholding

24^th Jun 2016

Director / PDMR Shareholding

22^nd Jun 2016

TR-1 notification of major interest in shares

22^nd Jun 2016

Director/PDMR Shareholding

21^st Jun 2016

Director Dealings

10^th Jun 2016

Pages:

19

Archive

2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011

Mount Sinai investments related

RNS announcements

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

Half-year Report

EKF Diagnostics announces its unaudited interim results for the six months ended 30 June 2019.

Notice of results

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it will release its interim results for the six months ended 30 June 2019 on Tuesday 10 September 2019.

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, provides the following trading update.

Cancellation of share options

EKF Diagnostics Holdings plc (AIM: EKF) announces that 250,000 share options over ordinary shares of 1 penny each granted to a PDMR of the Company have been cancelled at the election of the option holder in return for the payment of a one-off cash sum.

TR-1: Standard form for notification of major holdings

Standard form for notification of major holdings.

Product showcase

Copyright © 2024 | Powered by Intergage

Quick links

News and Events

Anemia and Hemoglobin testing

Diabetes and HbA1c testing

Support

Social media

EKF Diagnostics - web 50px

Please note: Not all products are available in all countries. Please check availability.

Privacy | Terms & Conditions | Terms of Sale | ESG Statement | UK Modern Slavery Act